CSIMarket
 
Abeona Therapeutics Inc   (ABEO)
Other Ticker:  
 
 
Price: $8.6300 $0.49 6.020%
Day's High: $8.87 Week Perf: 10.5 %
Day's Low: $ 8.03 30 Day Perf: 40.33 %
Volume (M): 463 52 Wk High: $ 9.01
Volume (M$): $ 3,996 52 Wk Avg: $4.32
Open: $8.11 52 Wk Low: $2.24



 Market Capitalization (Millions $) 214
 Shares Outstanding (Millions) 25
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing gene and cell therapies for rare and life-threatening genetic diseases. The company is dedicated to transforming the lives of patients suffering from rare genetic diseases by developing innovative treatments that address the underlying cause of the disease.

Abeona Therapeutics has a diverse pipeline of potential therapies, with a particular focus on treating patients with rare genetic conditions such as Sanfilippo syndrome, Batten disease, and epidermolysis bullosa. The company's therapies aim to either replace missing or malfunctioning genes or to modify the patient's own cells to produce the missing proteins.

The company is committed to conducting thorough research and running clinical trials to ensure the safety and efficacy of their therapies. In addition to developing new treatments, Abeona Therapeutics also collaborates with academic institutions and other companies to improve and expand the field of gene and cell therapies.

Overall, Abeona Therapeutics Inc. is a pioneering biopharmaceutical company that strives to develop revolutionary therapies for rare genetic diseases, providing hope to patients and their families.


   Company Address: 6555 Carnegie Avenue Cleveland 44103 OH
   Company Phone Number: 813-4701   Stock Exchange / Ticker: NASDAQ ABEO
   ABEO is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Abeona Therapeutics Grants Equity Awards to New Employees Under Nasdaq Rule 5635(c)(4); Records Significant Revenue Increase

Published Tue, Mar 5 2024 12:30 PM UTC

Abeona Therapeutics Inc., a leading biopharmaceutical company, has recently announced the granting of equity awards to new non-executive employees joining the organization. These awards have been approved in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, during the corresponding time period, Abeona Therapeutics Inc. witnessed a remarkable surge in revenue, dem...

Shares

Abeona Therapeutics' Strategic Employee Inducement Grants Spark Interest in Company Shares

Published Thu, Feb 1 2024 9:05 PM UTC

Abeona Therapeutics Grants Employee Inducement Awards - Impact on Company Shares
Abeona Therapeutics, a leading biopharmaceutical company, has recently announced the allocation of equity awards to new non-executive employees who have joined the company. The decision to grant these awards has been made in compliance with Nasdaq Listing Rule 5635(c)(4). With 24.797564 mil...

Management Announcement

Abeona Therapeutics: Securing $50 Million Credit Facility to Supercharge Growth and Rebound from Challenging Losses

Published Mon, Jan 8 2024 12:30 PM UTC

Abeona Therapeutics Secures $50 Million Credit Facility to Accelerate Growth
CLEVELAND, Jan. 08, 2024 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading biopharmaceutical company focused on developing transformative gene and cell therapies, announced today a major milestone in its financial strategy. The company has successfully secured a $50 million credit facility wi...

Shares

Abeona Therapeutics Fuels Growth with Employee Inducement Grants, Nurturing Talent for Long-term Success.

Published Fri, Dec 15 2023 12:30 PM UTC



On December 15th, 2023, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its recent grant of equity awards to new non-executive employees, in compliance with Nasdaq Listing Rule 5635(c)(4). These inducement grants aim to strengthen the company's workforce and align the interests of its employees towards achieving long-term success. As of the writing of this articl...

Abeona Therapeutics Inc

Major Pharmaceutical Preparations Company Struggles to Achieve Profitability Amidst Record Revenue Surge in Fiscal Period Ending September 30, 2023

October 5, 2023
Abeona Therapeutics Inc, a major player in the Pharmaceutical Preparations sector, has announced impressive financial results for the fiscal three months ending on September 30, 2023. Despite posting a net loss of $11.836 million, the company witnessed a staggering revenue elevation of 723.611% year on year to $0.59 million. These results have caught many analysts and investors by surprise, especially given the decline of 4.77% experienced by the rest of the Major Pharmaceutical Preparations sector during the reporting period.
Comparing the current figures to the previous reporting season, Abeona Therapeutics Inc's earnings per share fell from $0.92 to -$0.48 per share, while revenue tumbled by -84.861%, from $3.92 million. These numbers indicate a significant decrease in profitability, which needs further analysis to determine the root causes.






 

Abeona Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com